Medical devices industry venture financing deals in October 2019 total $400.74m in US

14 November 2019 (Last Updated November 14th, 2019 09:16)
Medical devices industry venture financing deals in October 2019 total $400.74m in US

Total medical devices industry venture financing deals in October 2019 worth $400.74m were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 34.7% over the previous month and a drop of 27% when compared with the last 12-month average of $548.72m.

The US held a 70.9% share of the global medical devices industry venture financing deal value that totalled $565.49m in October 2019.

In terms of deal activity, the US recorded 50 deals during October 2019, marking an increase of 4.2% over the previous month and a drop of 13.8% over the 12-month average.

The US medical devices industry venture financing deals in October 2019: Top deals

The top five medical devices industry venture financing deals accounted for 42.9% of the overall value during October 2019.

The combined value of the top five medical devices venture financing deals stood at $172m, against the overall value of $400.74m recorded for the month.

The top five medical devices industry deals of October 2019 tracked by GlobalData were:

1) Charles River Ventures, Greenoaks Capital Management, GV Management, Kleiner Perkins Caufield & Byers and Threshold Ventures’ $50m venture financing of Viz.ai

2) The $37m venture financing of CorneaGen by Flying L Partners, KKR and Petrichor Healthcare Capital Management

3) Amzak Health, Aperture Venture Partners, LivaNova, Strategic Healthcare Investment Partners and USVP Management’s $33m venture financing of ShiraTronics

4) The $27m venture financing of PierianDx by ARUP Laboratories, ATW Partners, Health Catalyst Capital Management, Inova Health System, RTI International and SJF Ventures

5) Decheng Capital’s venture financing of Mynosys Cellular Devices for $25m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.